MilliporeSigma, a German company affiliated with Merck KGaA, has acquired Madison-based Mirus Bio for $600 million. Mirus Bio is a manufacturer of transfection regents used in gene therapies.
Dale Gordon, CEO of Mirus Bio, expressed excitement about the acquisition. He believes that MilliporeSigma’s broad portfolio, scale, and global reach will help take their business to new heights. The acquisition will allow them to serve more customers and patients worldwide.
MilliporeSigma’s Process Solutions business provides solutions for viral vector manufacturing, catering to cell and gene therapies from preclinical through commercial production. Their portfolio includes cell lines, culture media, processing chemicals, enzymes, and various systems and consumables essential for viral vector manufacturing processes.
In addition to manufacturing solutions, MilliporeSigma’s Life Science Services business offers contract testing and contract development and manufacturing organization services specifically for viral vector manufacturing. Matthias Heinzel, CEO of the Life Science business at Merck KGaA, emphasized the growing demand for viral vector-based therapies, projecting a 30% growth until 2028.
The acquisition is set to close in the third quarter of this year, marking an important milestone for both Mirus Bio and MilliporeSigma in expanding their offerings in the field of cell and gene therapies.
